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Experimental studies have implicated telomere dynamics in cardiomyocyte size and replication potential; shorter
telomeres mark attenuated proliferation and increased apoptosis. The authors examined whether this translates
into an impact of telomere length (TL) on left ventricular (LV) mass in the general population. In 334 randomly
selected Flemish participants (mean age¼ 46.5 years; 52.5% women), they measured TL in circulating leukocytes
using quantitative polymerase chain reaction, expressing it as telomere/genomic DNA ratio (T/S). After a median
7.4 years of follow-up (interquartile range, 6.2–8.5) during 1996–2007, they measured LV mass by echocardiog-
raphy. In multivariable-adjusted analyses accounting for sex, age, body weight and height, systolic blood pressure,
and antihypertensive drug use, LV mass and LV mass index significantly increased with mean leukocyte TL in the
entire population and in the 198 normotensive subjects. For a 1-standard-deviation increment in T/S ratio, LV mass
(mean ¼ 170 g) and LV mass index (mean ¼ 92 g/m2) increased by 5.20 g (P ¼ 0.003) and 2.70 g/m2 (P ¼ 0.004),
respectively, in all subjects and by 8.03 g (P¼ 0.0001) and 3.74 g/m2 (P¼ 0.0007) in normotensive subjects. There
were corresponding associations with LV wall thicknesses (P < 0.007) but not LV internal diameter (P ¼ 0.26) in
normotensive subjects. Longer mean leukocyte TL is associated with increased LV mass, particularly in normo-
tensive subjects. This association could have a biologic basis related to the role of TL in determining cardiomyocyte
size and replication potential.
heart ventricles; myocytes, cardiac; population; telomere
Abbreviations: CI, confidence interval; LV, left ventricular; SD, standard deviation; TERT, telomerase reverse transcriptase.
Telomeres—the specialized DNA-protein structures cap-
ping the ends of eukaryotic chromosomes—are essential for
maintaining chromosomal stability and integrity (1). Telo-
meres consist of a large number of tandem repeats of a sim-
ple DNA sequence (TTAGGG in humans), and telomere
length is an important determinant of telomere function
(2). Telomere length depends on many factors, including
inheritance, cellular replicative history, and the activity level
of telomerase—a reverse transcriptase consisting of an RNA
component and a catalytic protein component, telomerase
reverse transcriptase (TERT), that has the ability to add
telomere repeats (2, 3). In the absence of telomerase, be-
cause DNA polymerase cannot fully complete the replica-
tion of the 3# end of linear DNA, telomeres progressively
shorten with repeated cell divisions (4). In many types of
cells, senescence and subsequent cell death often occurs
when the mean telomere length reaches a critical value
(5, 6).
Previously, the number of muscle cells in the mammalian
myocardium was thought to be defined at birth. However,
recent evidence from both experimental and human studies
suggests that the myocardium consists of a heterogeneous
population of cardiomyocytes, characterized by ongoing
cell death and cell regeneration during the entire life span
(7–9). Furthermore, several observations suggest an impor-
tant role for telomeres and telomerase in this process. With
aging, telomerase knockout mice showed shortening of telo-
meres, attenuated proliferation and increased apoptosis of
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cardiomyocytes, and a higher risk of cardiac remodeling and
left ventricular (LV) failure (10, 11). On the other hand,
enhanced expression of TERT in rat cardiomyocytes pre-
served telomerase activity and telomere length and induced
cardiomyocyte hypertrophy without fibrosis or loss of func-
tion (12). These observations suggest that telomere length
may be an important determinant of the rate at which car-
diomyocyte attrition occurs with age. In turn, because car-
diomyocytes are the major contributor to LV mass, this
could affect LV mass. Therefore, we tested the hypothesis
that telomere length predicts LV mass in a random sample of
the general population.
MATERIALS AND METHODS
Study participants
Study participants were from the Flemish Study on Envi-
ronment, Genes and Health Outcomes, consisting of a ran-
dom population sample, stratified by sex and age, selected
from a geographically defined area in northern Belgium.
Officials from 7 municipalities gave us listings of all inhab-
itants, sorted by address. Households, defined as all subjects
living at the same address, were the sampling unit. We num-
bered households consecutively and generated a random-
number list through the use of a SAS random function
(SAS Institute Inc., Cary, North Carolina). Households with
a number matching the list were invited to participate. Fur-
ther details on the sampling frame are given elsewhere (13).
Initial assessment of the study population took place
between 1996 and 2000 and involved 638 subjects. Follow-
up took place between 2005 and 2007. The participation
rate among the subjects contacted in 2005–2007 averaged
72.3%. Blood for the follow-up DNA extraction could not
be obtained from 260 participants, because they did not
consent (n ¼ 145), had died (n ¼ 24), were bedridden or
institutionalized (n ¼ 19), or had moved out of the area or
could not be reached (n ¼ 72). Thus, we reexamined 378
former participants at our field center, including echocardi-
ography. We excluded 32 subjects from the present analysis
because of LV remodeling due to myocardial infarction or
coronary revascularization (n ¼ 9), valvular heart disease
(n¼ 16), atrial fibrillation (n¼ 5), or an artificial pacemaker
(n ¼ 2). We discarded a further 12 subjects because the
echocardiogram (n¼ 5) or DNA for telomere measurements
(n ¼ 7) was of insufficient quality. Thus, the number of
participants statistically analyzed totaled 334.
The Ethics Committee of the University of Leuven
(Leuven, Belgium) approved the study protocol (baseline
and follow-up), and participants provided written informed
consent.
Clinical measurements
We used a validated questionnaire to inquire about life-
style, medical history, medication use, smoking, and alcohol
drinking. The questionnaire also obtained detailed informa-
tion on the total number of hours spent in sports and occu-
pational activities, including school attendance for younger
people. With the use of published tables, we estimated the
amount of energy spent in physical activity from body
weight, time devoted to work and sports, and types of phys-
ical activity reported (14). Trained nurses measured anthro-
pometric characteristics and took blood pressure 5 times
consecutively to the nearest 2 mm Hg after the subject
had been seated for at least 5 minutes. Normotension was
defined as untreated blood pressure below 140 mm Hg (sys-
tolic) and below 90 mm Hg (diastolic) at both baseline
(1996–2000) and follow-up (2005–2007). Hypertension
was defined as a blood pressure equal to or higher than these
thresholds or the use of antihypertensive medication at base-
line, follow-up, or both (15). Body mass index was calcu-
lated as weight in kilograms divided by the square of height
in meters.
Echocardiography at follow-up assessment
(2005–2007)
All echocardiograms were performed and analyzed by
a single experienced physician (T. K.) using a Vivid 7 Pro
device (GE Vingmed Ultrasound, Horten, Norway) inter-
faced with a 2.5- to 3.5-MHz phased-array probe as de-
scribed elsewhere (16). Briefly, with the subject in partial
left decubitus and breathing normally, parasternal long and
short axes and apical 4- and 2-chamber long-axis views
were obtained, together with a simultaneous electrocardio-
graphic signal. All recordings included at least 5 cardiac
cycles, and results were digitally stored for off-line analysis.
M-mode echocardiograms of the left ventricle were re-
corded from the parasternal long-axis view under control
of the 2-dimensional image. The ultrasound beam was
positioned just below the mitral valve at the level of the
posterior chordae tendineae.
Images were analyzed at a work station on a computer
using EchoPac software, version 4.0.4 (GE Vingmed
Ultrasound). To improve accuracy, results from 3 heart
cycles were averaged. The LV internal diameter and inter-
ventricular septal and posterior wall thickness were mea-
sured at end-diastole from 2-dimensional guided M-mode
tracings, according to current guidelines (17). End-
diastolic LV dimensions were used to calculate LV mass
by means of an anatomically validated formula (18).
The ejection fraction was calculated as (end-diastolic
volume  end-systolic volume)/LV end-diastolic volume.
LV mass index was defined as LV mass divided by body
surface area, calculated as body weight0.425 (in kg)3 body
height0.725 (in cm) 3 0.007184. Relative wall thickness
was calculated as (23 posterior wall)/LV internal diameter
at end-diastole. LV concentric remodeling was defined as
a relative wall thickness exceeding 0.43. LV hypertrophy
was defined as an LV mass index exceeding 110 g/m2 in
women and 125 g/m2 in men (19). To determine intraob-
server reproducibility, the echocardiographer (T. K.)
analyzed the echocardiograms of 17 subjects twice. The
intraobserver reproducibility coefficient of a measurement
was the 2-standard-deviation (SD) interval around the
mean of the relative differences across pairwise readings.
The intraobserver reproducibility was 2.2% for LV internal
end-diastolic diameter, 4.6% for LV wall thickness, and
4.3% for LV mass.
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Measurement of telomere length in DNA obtained at
baseline (1996–2000) and at follow-up (2005–2007)
Genomic DNA was extracted from peripheral blood, us-
ing the phenol method. To measure telomere length, we
used real-time quantitative polymerase chain reaction as de-
scribed previously (20, 21). We determined the relative ratio
of telomere repeat copy number (T) to single-copy gene
copy number (36B4 gene; S), with all samples being com-
pared with the same reference DNA sample. Therefore,
telomere length was expressed as the T/S ratio. Samples
were analyzed in duplicate wells together with a duplicate
calibrator well (K562 cell line genomic DNA) and a no-
template control well (to test for contamination). Determi-
nation of T and S quantities was performed by means of
RotorGene comparative quantitation software (Corbett Re-
search, Sydney, Australia) (21). The coefficients of variation
between duplicate measurements within the same run were
1.9% (T), 1.4% (S), and 2.6% (T/S). To test for interrun
variation, we reanalyzed 12.5% of the samples on a separate
day; the coefficient of variation was 4.2%.
Statistical analysis
For database management and statistical analysis, we
used SAS software, version 9.1. We investigated associa-
tions between variables by means of simple and multiple
linear regression. For continuous LV traits, we adjusted
the models for possible covariables based on our previous
publications (22) with known physiologic relevance for left
ventricle structure and confirmed in the present study by
stepwise linear regression. We searched for variables asso-
ciated with T/S ratio using stepwise linear regression. The
significance level for variables to enter and stay in the re-
gression models was set at P < 0.05. Common covariables
significantly associated with the explanatory variable (T/S
ratio) and the outcome variables (LV traits) were age and
sex. We tested the association of continuous traits with
the T/S ratio by use of a mixed model. This technique
allows accounting for covariables as well as for the non-
independence of observations within families. We expressed
multivariable-adjusted effect sizes for a 1-SD increase in the
explanatory variables. To calculate residuals, we adjusted
the T/S ratio for age and sex and LV traits for age, sex,
anthropometric characteristics, and systolic blood pressure.
All P values were for 2-sided tests.
RESULTS
Characteristics of participants
The cohort with telomere measurements at baseline in-
cluded 334 subjects, of whom 181 (54.2%) were women and
136 (40.7%) were persons with hypertension (treated but not
controlled, 38 patients; treated and controlled, 36 patients;
untreated, 62 patients). The median interval between the
baseline T/S measurement and cardiac phenotyping was
7.4 years (interquartile range, 6.2–8.5). Table 1 shows the
clinical characteristics of participants in the entire study
population and those subjects who were normotensive at
both baseline (1996–2000) and follow-up (2005–2007) (n ¼
198) or hypertensive at baseline, follow-up, or both (n¼ 136).
Table 1 also shows corresponding echocardiographic charac-
teristics. Overall, 28 subjects (8.4%) had LV hypertrophy
(Table 1). In the normotensive group, 4 subjects (2.0%) had
eccentric LV hypertrophy and 12 subjects (6.1%) had a normal
LV mass but increased relative wall thickness (concentric
remodeling) (Table 1). In hypertensive patients, concentric
and eccentric hypertrophy and concentric remodeling were
present in 4.4%, 13.2%, and 17.6%, respectively (Table 1).
Both at baseline and at follow-up, age was a significant de-
terminant of the T/S ratio (P < 0.0001; Figure 1), accounting
for 14.2% and 16.0% of the variance, respectively. In cross-
sectional analyses of the baseline and follow-up data, estimates
of the annual decrease in the T/S ratio were 0.0067 (95%
confidence interval (CI): 0.0084, 0.0050) and 0.0070
(95% CI:0.0086,0.0054), respectively. The longitudinally
measured annual T/S attrition rate based on the differences
between baseline and follow-up averaged 0.0077 (SD,
0.018) per year (95% CI: 0.0086, 0.0054), showing con-
cordance with the cross-sectional estimates. The 5th–95th per-
centiles of the T/S ratio changes ranged from0.033 to 0.023,
reflecting that in some subjects telomere length remained un-
changed or even increased slightly over time. In unadjusted
analysis, T/S ratio was lower in hypertensive patients than in
normotensive subjects (Table 1), but this was because hyper-
tensive subjects were older (47.0 years vs. 59.1 years (P <
0.0001); Table 1). After adjustment for age, there was no
difference in telomere length between normotensive and hy-
pertensive subjects (P > 0.70). In our study, telomere length
was not associated with any of the anthropometric measure-
ments, including body mass index analyzed as a continuous
(P  0.36) or categorical (P ¼ 0.46) trait.
Association between LV phenotypes and telomere
length
We analyzed the association between LV phenotypes and
telomere length in multivariable-adjusted analyses while
accounting for sex, age, body weight and height, systolic
blood pressure, and use of antihypertensive drugs. There
was a significant positive association of both LV mass and
LV mass index at the follow-up examination with T/S ratio
at baseline in all subjects and in the normotensive subgroup
(Table 2). In all participants, LV mass and LV mass index
were 5.20 g (P ¼ 0.003) and 2.70 g/m2 (P ¼ 0.004) greater,
respectively, for a 1-SD increment in the T/S ratio (approx-
imately 0.75 kilobase pairs). In the normotensive subgroup,
the corresponding effect sizes were 8.03 g (P ¼ 0.0001) and
3.74 g/m2 (P ¼ 0.0007), respectively, but the associations
were not significant in the hypertensive subgroup (Table 2).
There were corresponding associations with LV wall thick-
ness, particularly noticeable in the normotensive subjects,
but no association with LV internal diameter (Table 2).
These findings were consistent when we used the residuals
of LV mass and the T/S ratio to remove the effect of age
and anthropometric characteristics rather than to adjust for
these covariables in multiple regression analyses (Figure 2).
The cross-sectional and multivariable-adjusted associa-
tions between the LV traits and the T/S ratio at follow-up
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(2005–2007) were somewhat attenuated in comparison with
the associations seen with baseline telomere length, but
trends were similar and the positive association in the nor-
motensive subgroup remained highly significant (Table 3).
However, as Table 3 shows, when we additionally included
the longitudinally measured telomere attrition rate in the
multivariable-adjusted models, the confidence intervals for
the association between LV wall thickness or LV mass and
the T/S ratio at follow-up narrowed. In all subjects, the
parameter estimates for a 1-SD increase in the telomere
attrition rate were 0.17 mm (95% CI: 0.29, 0.052;
P ¼ 0.005) for LV wall thickness and 4.27 g (95%
CI: 7.49, 1.05; P ¼ 0.009) for LV mass. In normo-
tensive subjects, these estimates were 0.17 mm (95%
CI: 0.31, 0.025; P ¼ 0.02) and 4.09 g (95%
CI: 8.37, 1.58; P ¼ 0.004), respectively.
Table 1. Characteristics of Subjects Included in a Study of Telomere Length and Left Ventricular Mass, Belgium, 1996–2007
Characteristic
All Subjects
(n 5 334)
Normotensive Subjects
(n 5 198)
Hypertensive Subjects
(n 5 136) P Value
No. % Mean (SD) No. % Mean (SD) No. % Mean (SD)
Female sex 181 53.2 106 53.5 71 52.2 0.81
Age, years 51.9 (14.3) 47.0 (13.5) 59.1 (12.2) <0.0001
Body weight, kg 74.4 (12.9) 72.1 (12.3) 77.7 (13.0) <0.0001
Body height, cm 168.1 (9.0) 169.0 (8.9) 166.7 (9.02) 0.18
Body mass indexa 26.3 (3.8) 25.2 (3.6) 27.9 (3.5) <0.0001
Waist:hip ratio 0.86 (0.077) 0.84 (0.075) 0.89 (0.072) <0.0001
Systolic blood pressure, mm Hg 129.7 (17.1) 119.5 (10.0) 144.5 (14.2) <0.0001
Diastolic blood pressure, mm Hg 80.0 (9.2) 75.9 (6.8) 85.8 (9.1) <0.0001
Smoking 71 21.3 53 26.8 18 13.2 0.003
Alcohol drinking 140 41.9 82 41.4 58 42.6 0.82
Total calorie expenditure,
kcal/day
1,875 (599) 1,840 (593) 1,924 (605) 0.21
Hypertensionb 136 40.7 136 100
Treatment for hypertension 74 22.2 74 54.4
T/S ratioc at baseline
(1996–2000)
1.82 (0.26) 1.84 (0.27) 1.78 (0.26) 0.03
T/S ratio at follow-up
(2005–2007)
1.76 (0.26) 1.80 (0.26) 1.71 (0.25) 0.003
T/S annual attrition rate 0.0077 (0.018) 0.0063 (0.019) 0.0097 (0.016) 0.10
Echocardiography
LV internal end-diastolic
diameter, mm
49.6 (4.8) 49.9 (4.7) 49.3 (5.1) 0.28
Interventricular septum, mm 10.0 (1.8) 9.4 (1.6) 10.8 (1.8) <0.0001
Posterior wall, mm 8.9 (1.4) 8.5 (1.3) 9.6 (1.3) <0.0001
Relative wall thickness 0.38 (0.076) 0.36 (0.067) 0.42 (0.76) <0.0001
LV mass, g 169.9 (45.9) 158.9 (41.7) 185.9 (47.2) <0.0001
LV mass indexd, g/m2 91.8 (20.1) 86.6 (18.0) 99.3 (20.7) <0.0001
LV hypertrophye 28 8.4 4 2.0 24 17.6 <0.0001
LV concentric remodelingf 36 10.8 12 6.1 24 17.6 0.0008
Ejection fractiong 68.8 (7.8) 67.7 (7.6) 70.5 (7.8) 0.0007
Abbreviations: LV, left ventricular; SD, standard deviation.
a Weight (kg)/height (m)2.
b Hypertension was defined as a blood pressure of at least 140 mm Hg (systolic) or 90 mm Hg (diastolic) or the use of antihypertensive drugs at
baseline, follow-up, or both.
c T/S ratio, relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S).
d LV mass index was defined as LV mass divided by body surface area, calculated as body weight0.425 (in kg) 3 body height0.725 (in cm) 3
0.007184.
e LV hypertrophy is an LV mass index exceeding 110 g/m2 in women and 125 g/m2 in men. P values relate to the significance of the differences
between normotensive and hypertensive participants.
f LV concentric remodeling was defined as a relative wall thickness exceeding 0.43.
g Relative volume difference (%) during the cardiac cycle.
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DISCUSSION
The key finding of our study was that leukocyte telomere
DNA length was associated with LV mass both longitudi-
nally and cross-sectionally. To our knowledge, our study is
the first population-based study demonstrating in a prospec-
tive manner an association between LV mass and telomere
length. The median interval between the baseline telomere
length measurement and the echocardiographic examination
was 7.4 years. The association was stronger in normotensive
subjects. Along similar lines, Vasan et al. (23) recently
reported a positive cross-sectional association between
multivariable-adjusted LV mass and telomere length mea-
sured by Southern blot analysis in 850 Framingham Heart
Study participants. In our study, the estimated and measured
annual decreases in T/S ratio were 0.0070 and 0.0080,
which is in good agreement with the attrition rates observed
in other populations measured with this technique (24, 25).
Using the relation between polymerase chain reaction-based
and Southern blot measurements of telomere length (20, 21,
24), this corresponds to 10–37 base pairs of telomere
sequence per year.
Our findings are consistent with and extend to population-
level previous work linking myocardial biology with telo-
mere dynamics. It is now clear that there is a continuous
regeneration of cardiomyocytes throughout life mediated by
Table 2. Multivariable-Adjusted Associations Between Left Ventricular Traits and T/S Ratioa Measured at Baseline (1996–2000), Overall and by
Hypertension Status, Belgium, 1996–2007
Echocardiographic
Characteristic at
Follow-up
(2005–2007)
T/S Ratio at Baseline (1996–2000)
P-InteractionbAll Subjects (n 5 334) Normotensive Subjects (n 5 198) Hypertensive Subjects (n 5 136)
Estimatec 95% CI P Value Estimate 95% CI P Value Estimate 95% CI P Value
Interventricular
septum, mm
0.165 0.005, 0.335 0.06 0.263 0.062, 0.465 0.007 0.029 0.273, 0.328 0.85 0.27
Posterior wall, mm 0.128 0.001, 0.258 0.05 0.240 0.073, 0.406 0.004 0.015 0.200, 0.224 0.88 0.21
LV diastolic
diameter, mm
0.181 0.265, 0.627 0.24 0.312 0.244, 0.884 0.26 0.055 0.562, 0.788 0.88 0.46
LV mass, g 5.20 1.81, 8.61 0.003 8.03 4.08, 12.0 0.0001 2.06 4.26, 8.40 0.52 0.12
LV mass indexd,
g/m2
2.70 0.88, 4.50 0.004 3.74 1.77, 5.88 0.0007 0.905 2.51, 4.32 0.59 0.19
Abbreviations: CI, confidence interval; LV, left ventricular.
a T/S ratio, relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S).
b Significance of the interaction between T/S ratio and hypertension status.
c Estimates are expressed for a 1-standard-deviation (0.26) higher T/S ratio. Estimates for LV traits were adjusted for sex, age, body weight and
height (not applicable to LV mass index), waist:hip ratio, total daily calorie expenditure, systolic blood pressure, and use of antihypertensive drugs
(not applicable to normotensive subjects).
d LV mass index was defined as LV mass divided by body surface area, calculated as body weight0.425 (in kg) 3 body height0.725 (in cm) 3
0.007184.
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Figure 1. Relation between the relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S) (T/S ratio) and
age at A) baseline (1996–2000) (n¼ 334; y¼ 2.12 0.00703 age; P< 0.0001) and B) follow-up (2005–2007) (n¼ 334; y¼ 2.13 0.00683 age;
P < 0.0001), Belgium. Dotted lines mark the 95% confidence interval for the prediction of the T/S ratio based on age in individual subjects.
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a selected group of non-terminally differentiated cells (26).
Such cells demonstrate telomere shortening and a senescent
phenotype with age (27). In hearts from aged rats, Kajstura
et al. (9) found that approximately 16% of cardiomyocytes
showed telomere shortening.
More direct evidence for involvement of telomeres in car-
diomyocyte size and regeneration comes from experimental
manipulation of telomere length of cardiomyocytes. Telomere
shortening in second- and fifth-generation telomerase knock-
out mice was accompanied by attenuation in cardiomyocyte
proliferation, increased apoptosis, and cardiomyocyte hyper-
trophy (10). These cell impairments are concomitant with LV
dilation, thinning of the wall, reduction of LV mass, and car-
diac dysfunction in the later (fifth) generation of telomerase
knockout mice (10). On the other hand, forced expression of
TERT in cardiac muscle in mice was sufficient to rescue tel-
omerase activity and telomere length and delay cardiac cell-
cycle exit (12). In the first month after birth, the left ventricle
in these mice was hypercellular, with increased myocyte den-
sity and DNA synthesis (12). By 12 weeks, cell cycling sub-
sided; instead, cell enlargement (hypertrophy) was seen (12),
but without fibrosis or impaired function, unlike other forms
of induced cardiac growth (28). Thus, we speculate that under
normal circumstances, subjects with longer telomeres might
have larger cardiomyocytes and better regenerative capacity
and hence maintain LV mass better. The finding that a greater
LV posterior wall thickness was associated with a lower rate
of telomere attrition from baseline to follow-up is consistent
with this hypothesis. However, we cannot exclude the possi-
bility that the association between LV mass and telomere
length is not direct but is mediated by an unmeasured third
factor which influences both LV mass and telomere length,
such as oxidative stress or physical activity (29).
The above interpretation of the association between telo-
mere length and LV mass, while consistent with experimen-
tal observations, is based on the assumption that mean
leukocyte telomere length reflects the telomere length of
cardiomyocytes. This remains to be directly shown. None-
theless, telomere length has a strong genetic determination
(30–32). Several studies have shown high intraindividual
correlation of mean telomere length in different tissues, in-
cluding leukocytes and vascular tissues (33, 34). In our
study, the association between LV mass and telomere length
was particularly significant in subjects who were normoten-
sive at baseline and follow-up and in whom long-standing
hemodynamic factors or treatment was unlikely to mask this
association.
Pathologic cardiac growth induced by mechanical load
(blood pressure) is characterized by enlargement and disor-
ganization of cardiomyocytes, interstitial fibrosis, ‘‘fetal’’
cardiac gene induction, and apoptosis (28). In contrast, phys-
iologically increased LV mass is associated with normal car-
diac structure and normal or enhanced cardiac function (35).
LV hypertrophy is associated with a poor prognosis and in-
creased cardiovascular mortality and morbidity (19). In our
normotensive group, in which we found a strong positive
association between LV mass and T/S ratio, only 4 subjects
(2.0%) had mild eccentric LV hypertrophy (mainly due to an
increase in LV diastolic diameter). Thus, in our normotensive
subjects, LV mass was distributed within a clinically normal
(physiologic) range. However, even within this range, we
demonstrated significantly different values of LV mass across
quartiles of T/S ratio (Appendix Table 1). It is notable that in
the study by Vasan et al. (23), the positive association be-
tween LV mass and telomere length was stronger in hyper-
tensive subjects with pathologic LV hypertrophy than in
normotensive subjects. The Framingham investigators did
not provide an explanation for this somewhat unexpected
finding, especially since some investigators have reported
shorter telomeres in subjects with hypertension (36). The
reasons for the difference in this regard between their obser-
vations and ours remain to be clarified.
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Figure 2. Correlations of the residuals of A) left ventricular mass (LVM) (r ¼ 0.26, P ¼ 0.0002), B) the posterior wall (r ¼ 0.20, P ¼ 0.0057), and
C) the interventricular septum (IVS) (r ¼ 0.18, P ¼ 0.011) at follow-up (2005–2007) with the residuals of relative ratio of telomere repeat copy
number (T) to single-copy gene copy number (36B4 gene; S) (T/S ratio) at baseline (1996–2000) in normotensive subjects, Belgium. Residuals
were computed to remove the variance explained by age and anthropometric characteristics. Dotted lines mark the 95% confidence interval for the
prediction of left ventricular traits based on the T/S ratio in individual subjects with the effects of age and anthropometric characteristics removed.
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The association between LV mass and telomere length at
follow-up seemed attenuated in the cross-sectional analysis
as compared with the analysis with telomere length mea-
sured on average 7.4 years earlier. Although this may simply
reflect chance (as the effect sizes observed in the normoten-
sive group at the 2 time points were not statistically differ-
ent), it may also reflect a natural gradual exhaustion of the
regenerative capacity provided by longer telomeres with
increasing age. Therefore, just as in the case of hypertensive
subjects, where earlier increased replicative stress might
explain the loss of any association between LV mass
and telomere length, increasing age would also tend to at-
tenuate this relation. We noticed that in the last age quartile
(>61.5 years), the association between LV mass and T/S
ratio was significantly attenuated (Appendix Table 2). The
finding that a lower rate of telomere attrition from baseline
to follow-up was associated with greater LV wall thickness
and LV mass is consistent with this hypothesis.
Given the importance of LV mass as a determinant of LV
function, our finding that mean leukocyte telomere length
predicts LV mass has potential clinical relevance. Indeed, in
very elderly patients, mean leukocyte telomere length has
been shown to be positively correlated with ejection frac-
tion, with 1-SD-longer telomeres being associated with a
5% higher ejection fraction (37). Conversely, other studies
have shown that mean leukocyte telomere length is shorter
in patients with chronic heart failure than in age-matched
controls (38). Furthermore, the severity of heart failure is
inversely correlated with telomere length (38). This suggests
that exhaustion of the replicative capacity within the heart as
a consequence of shorter telomeres may be involved in the
progression to heart failure and may determine its severity.
Direct myocardial studies corroborate this possibility. Using
confocal microscopy, Chimenti et al. (8) compared endo-
myocardial biopsies from 19 elderly patients with dilated
myopathy with specimens from 7 aged-matched subjects
with normal LV function. Myocytes from the diseased
hearts showed a 39% reduction in average telomere length
and a higher level of cell apoptosis and necrosis compared
with specimens from healthy controls (8). Along similar
lines, Oh et al. (39) demonstrated that dilated failing human
hearts have telomeres that are 25% shorter than those of
aged-matched controls, with decreased expression of telo-
mere repeat-binding factor 2 and marked activation of DNA
Table 3. Multivariable-Adjusted Associations Between Left Ventricular Traits and T/S Ratioa Measured at Follow-up (2005–2007), Overall and
by Hypertension Status, Belgium, 1996–2007
Echocardiographic
Characteristic at
Follow-up
(2005–2007)
T/S Ratio at Follow-up (2005–2007)
P- InteractionbAll Subjects (n 5 334) Normotensive Subjects (n 5 198) Hypertensive Subjects (n 5 136)
Estimatec 95% CI P Value Estimate 95% CI P Value Estimate 95% CI P Value
Interventricular
septum, mm
Model 1d 0.109 0.065, 0.283 0.22 0.203 0.005, 0.416 0.05 0.007 0.320, 0.304 0.96 0.35
Model 2e 0.146 0.031, 0.611 0.11 0.250 0.039, 0.304 0.021 0.003 0.312, 0.338 0.98
Posterior wall, mm
Model 1 0.042 0.091, 0.175 0.53 0.161 0.007, 0.328 0.06 0.091 0.315, 0.130 0.41 0.15
Model 2 0.086 0.047, 0.224 0.20 0.213 0.042, 0.390 0.016 0.055 0.278, 0.169 0.62
LV diastolic
diameter, mm
Model 1 0.112 0.343, 0.567 0.63 0.195 0.369, 0.762 0.49 0.028 0.731, 0.785 0.94 0.66
Model 2 0.130 0.338, 0.598 0.58 0.250 0.343, 0.842 0.41 0.034 0.728, 0.806 0.93
LV mass, g
Model 1 3.33 0.20, 6.86 0.06 5.85 1.79, 9.88 0.005 0.018 6.32, 6.82 0.93 0.12
Model 2 4.29 0.70, 7.85 0.019 7.28 3.15, 11.4 0.0007 0.874 5.82, 7.57 0.79
LV mass indexf,
g/m2
Model 1 1.70 0.20, 3.59 0.08 2.75 0.56, 5.00 0.01 0.208 3.33, 3.74 0.91 0.16
Model 2 2.13 0.21, 4.06 0.029 3.35 1.11, 5.59 0.004 0.554 3.02, 4.13 0.75
Abbreviations: CI, confidence interval; LV, left ventricular.
a T/S ratio, relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S).
b Significance of the interaction between T/S ratio and hypertension status.
c Estimates are expressed for a 1-standard-deviation (0.26) higher T/S ratio.
d In model 1, estimates for LV traits were adjusted for sex, age, body weight and height (not applicable to LV mass index), waist:hip ratio, total
daily calorie expenditure, systolic blood pressure, and use of antihypertensive drugs (not applicable to normotensive subjects).
e In model 2, estimates were additionally adjusted for the longitudinally assessed telomere attrition rate.
f LV mass index was defined as LV mass divided by body surface area, calculated as body weight0.425 (in kg) 3 body height0.725 (in cm) 3
0.007184.
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damage response kinase (checkpoint kinase 2). Taken to-
gether, the findings indicate that telomere dynamics and
their change with age and under stress play an important
role in determining cardiac function.
The results in the present study must be interpreted within
the context of its limitations and strengths. First, as dis-
cussed above, we measured telomere length in easily acces-
sible circulating leukocytes; whether this measure reflects
telomere length in cardiomyocytes remains to be confirmed.
Second, variables reflecting LV structure are quantitative
traits prone to measurement error. In the present study, 1
experienced observer performed all echocardiograms, with
high intraobserver reproducibility.
In summary, longer mean leukocyte telomere length is
associated with increased LV mass, particularly in normo-
tensive subjects. The association could have a biologic basis
related to the role of telomere length in determining cardi-
omyocyte replication. Whether the association can aid in
risk stratification for heart failure and whether cardiac telo-
mere dynamics can be manipulated for clinical benefit
require further investigation.
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Appendix Table 1. Multivariable Left Ventricular Traits of Participants According to Quartile of T/S Ratioa Measured at Baseline (1996–2000),
Overall and by Hypertension Status, Belgium, 1996–2007
Characteristic
Quartile of T/S Ratio (1996–2000)
1 2 3 4
Estimateb 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI
All subjects (n 5 82) (n 5 86) (n 5 83) (n 5 83)
T/S ratio cutpoints <1.64 1.64–1.79 1.80–1.99 ‡2.00
LV traits
Interventricular
septum, mm
9.8 9.5, 10.2 10.3 9.9, 10.6 10.1 9.8, 10.5 10.5 10.1, 10.8
Posterior wall, mm 9.0 8.7, 9.3 9.2 8.9, 9.5 9.2 8.9, 9.5 9.3 9.0, 9.6
LV diastolic
diameter, mm
49.1 48.1, 50.1 49.0 48.0, 50.0 49.4 48.5, 50.4 49.4 48.4, 50.4
LV mass, g 163 156, 170 170 164, 177 174 167, 180 177 170, 184
LV mass indexc, g/m2 88 84, 91 92 88, 96 93 90, 97 95 91, 99
Normotensive subjects (n 5 49) (n 5 49) (n 5 50) (n 5 50)
T/S ratio cutpoints <1.66 1.66–1.81 1.82–2.05 ‡2.06
LV traits
Interventricular
septum, mm
9.0 8.6, 9.4 9.5 9.1, 9.9 9.3 8.9, 9.6 9.8 9.4, 10.2
Posterior wall, mm 8.2 7.9, 8.6 8.6 8.3, 9.0 8.6 8.3, 9.0 8.8 8.5, 9.2
LV diastolic
diameter, mm
50.0 48.8, 51.2 48.8 47.6, 50.0 50.2 48.9, 51.4 50.0 48.7, 51.3
LV mass, g 153 144, 161 155 147, 163 164 156, 172 170 161, 178
LV mass index, g/m2 84 79, 88 84 80, 88 88 84, 92 91 89, 96
Hypertensive subjects (n 5 33) (n 5 37) (n 5 33) (n 5 33)
T/S ratio cutpoints <1.64 1.64–1.79 1.80–1.99 ‡2.00
LV traits
Interventricular
septum, mm
11.0 10.4, 11.7 10.9 10.3, 11.5 11.0 10.3, 11.6 11.0 10.3, 11.6
Posterior wall, mm 9.7 9.3, 10.2 9.8 9.4, 10.2 9.7 9.2, 10.1 9.7 9.3, 10.2
LV diastolic
diameter, mm
48.2 46.6, 49.8 49.1 47.6, 50.6 49.8 48.3, 51.4 48.7 47.1, 50.2
LV mass, g 181 168, 194 185 173, 197 190 177, 203 185 172, 198
LV mass index, g/m2 97 90, 103 99 92, 105 102 95, 109 99 92, 106
Abbreviations: CI, confidence interval; LV, left ventricular.
a T/S ratio, relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S).
b Estimates are expressed for a 1-standard-deviation (0.26) higher T/S ratio. Estimates were adjusted for sex, age, body weight and height (not
applicable to LV mass index), waist:hip ratio, systolic blood pressure, use of antihypertensive drugs (not applicable to normotensive subjects), and
daily calorie expenditure.
c LV mass index was defined as LV mass divided by body surface area, calculated as body weight0.425 (in kg) 3 body height0.725 (in cm) 3
0.007184.
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Appendix Table 2. Age-Stratified Multivariable-Adjusted Associations Between Left Ventricular Mass and T/S Ratioa Measured at Baseline (1996–2000) or Follow-up (2005–2007) in the
Entire Study Population, Belgium, 1996–2007
T/S Ratio
Quartile of Age
1 (<43.7 Years)
(n 5 84; 75 (89.3%)
Normotensive)
2 (43.7–52.2 Years)
(n 5 83; 55 (66.3%)
Normotensive)
3 (52.3–61.5 Years)
(n 5 84; 41 (50.6%)
Normotensive)
4 (>61.5 Years)
(n 5 83; 27 (32.5%)
Normotensive)
Estimateb 95% CI P Value Estimateb 95% CI P Value Estimateb 95% CI P Value Estimateb 95% CI P Value
Baseline
(1996–2000)
3.77 2.34, 9.91 0.22 3.87 2.31, 10.1 0.21 10.1 2.65, 17.6 0.009 0.50 8.48, 9.49 0.91
Follow-up
(2005–2007)
1.54 4.52, 7.62 0.61 3.43 2.96, 9.88 0.29 7.88 0.36, 16.1 0.06 1.38 10.5, 7.75 0.76
Abbreviation: CI, confidence interval.
a T/S ratio, relative ratio of telomere repeat copy number (T) to single-copy gene copy number (36B4 gene; S).
b Estimates are expressed for a 1-standard-deviation (0.26) higher T/S ratio. Estimates were adjusted for sex, age, body weight and height, waist:hip ratio, systolic blood pressure, use of
antihypertensive drugs (not applicable to normotensive subjects), and total daily calorie expenditure.
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